0000000000725934

AUTHOR

F. Gasparini

showing 4 related works from this author

Mortality rate and risk factors for gastrointestinal bleeding in elderly patients

2019

Abstract Background Gastrointestinal bleeding (GIB) is burdened by high mortality rate that increases with aging. Elderly patients may be exposed to multiple risk factors for GIB. We aimed at defining the impact of GIB in elderly patients. Methods Since 2008, samples of elderly patients (age ≥ 65 years) with multimorbidity admitted to 101 internal medicine wards across Italy have been prospectively enrolled and followed-up (REPOSI registry). Diagnoses of GIB, length of stay (LOS), mortality rate, and possible risk factors, including drugs, index of comorbidity (Cumulative Illness Rating Scale [CIRS]), polypharmacy, and chronic diseases were assessed. Adjusted multivariate logistic regressio…

RegistrieMaleSettore MED/09 - Medicina Interna030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineRisk Factors80 and over030212 general & internal medicineHospital MortalityProspective StudiesRegistriesProspective cohort studyMultivariate AnalysiAged 80 and overDiverticulosisMortality rateDiverticulosiGastric ulcerAnemiaAnemia; Anticoagulant; Antiplatelet drug; Diverticulosis; Gastric ulcer; Multimorbidity; Internal MedicineItalyPlatelet aggregation inhibitorFemaleGastrointestinal HemorrhageAntiplatelet drugHumanGastrointestinal bleedingmedicine.medical_specialtyLogistic ModelAnemiaSocio-culturaleAnemia Anticoagulant Antiplatelet drug Diverticulosis Gastric ulcer Multimorbidity03 medical and health sciencesInternal medicineSeverity of illnessInternal MedicinemedicineHumansAnemia; Anticoagulant; Antiplatelet drug; Diverticulosis; Gastric ulcer; Multimorbidity; Aged; Aged 80 and over; Female; Gastrointestinal Hemorrhage; Hospital Mortality; Humans; Italy; Length of Stay; Logistic Models; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk Factors; Severity of Illness Index; MultimorbidityAgedPolypharmacybusiness.industryPlatelet Aggregation InhibitorRisk FactorAnemia; Anticoagulant; Antiplatelet drug; Diverticulosis; Gastric ulcer; MultimorbidityAnticoagulantMultimorbidityAnemia Anticoagulant Antiplatelet drug Diverticulosis Gastric ulcer Multimorbidity Aged Aged 80 and over Female Gastrointestinal Hemorrhage Hospital Mortality Humans Italy Length of Stay Logistic Models Male Multivariate Analysis Platelet Aggregation Inhibitors Prospective Studies Registries Risk Factors Severity of Illness Index MultimorbidityLength of Staymedicine.diseaseComorbidityProspective StudieLogistic ModelsMultivariate AnalysisbusinessPlatelet Aggregation Inhibitors
researchProduct

Search forBs0→μ+μ−andB0→μ+μ−Decays with CDF II

2011

A search has been performed for B{sub s}{sup 0} {yields} {mu}{sup +}{mu}{sup -} and B{sup 0} {yields} {mu}{sup +}{mu}{sup -} decays using 7 fb{sup -1} of integrated luminosity collected by the CDF II detector at the Fermilab Tevatron collider. The observed number of B{sup 0} candidates is consistent with background-only expectations and yields an upper limit on the branching fraction of {Beta}(B{sup 0} {yields} {mu}{sup +}{mu}{sup -}) < 6.0 x 10{sup -9} at 95% confidence level. We observe an excess of B{sub s}{sup 0} candidates. The probability that the background processes alone could produce such an excess or larger is 0.27%. The probability that the combination of background and the expe…

Flight directionNuclear and High Energy PhysicsParticle physicsMesonTevatronGeneral Physics and Astronomy01 natural sciences7. Clean energyLuminosityStandard Modellaw.inventionNuclear physicsParticle decaychemistry.chemical_compoundlawTheoryofComputation_ANALYSISOFALGORITHMSANDPROBLEMCOMPLEXITY0103 physical sciencesInvariant massLimit (mathematics)FermilabCollider010306 general physicsPhysicsMuon010308 nuclear & particles physicsBranching fractionSupersymmetryD0 experimentIMesCrystallographychemistryDecay lengthHigh Energy Physics::ExperimentLeptonPhysical Review Letters
researchProduct

Measurement of thett¯production cross section inpp¯collisions ats=1.96  TeVusing soft electronb-tagging

2010

The authors present a measurement of the t{bar t} production cross section using events with one charged lepton and jets from p{bar p} collisions at a center-of-mass energy of 1.96 TeV. A b-tagging algorithm based on the probability of displaced tracks coming from the event interaction vertex is applied to identify b quarks from top decay. Using 318 pb{sup -1} of data collected with the CDF II detector, they measure the t{bar t} production cross section in events with at least one restrictive (tight) b-tagged jet and obtain 8.9{sub -1.0}{sup +1.0}(stat.){sub -1.0}{sup +1.1}(syst.) pb. The cross section value assumes a top quark mass of m{sub t} is presented in the paper. This result is cons…

Top quarkCollider physicsHadronTevatronGeneral Physics and AstronomyElementary particleKinematicsElectronJet (particle physics)01 natural sciences7. Clean energyParticle identificationlaw.inventionlawInvariant massFermilabNuclear ExperimentQuantum chromodynamicsPhysicsLarge Hadron ColliderLuminosity (scattering theory)Supersymmetryb-taggingHadronizationTransverse planeProduction (computer science)Collider Detector at FermilabQuarkSemileptonic decayNuclear and High Energy PhysicsParticle physicsBar (music)Astrophysics::High Energy Astrophysical PhenomenaBottom quarkMeasure (mathematics)Standard ModelNuclear physicsCross section (physics)Particle decay0103 physical sciencesCollider010306 general physicsCompact Muon SolenoidMuonBranching fraction010308 nuclear & particles physicsHigh Energy Physics::PhenomenologyMultiplicity (mathematics)FermionVertex (geometry)Pair productionHigh Energy Physics::ExperimentEnergy (signal processing)Bar (unit)LeptonPhysical Review D
researchProduct

Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study

2019

&lt;b&gt;&lt;i&gt;Objective:&lt;/i&gt;&lt;/b&gt; Older people approaching the end of life are at a high risk for adverse drug reactions. Approaching the end of life should change the therapeutic aims, triggering a reduction in the number of drugs.&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;The main aim of this study is to describe the preventive and symptomatic drug treatments prescribed to patients discharged with a limited life expectancy from internal medicine and geriatric wards. The secondary aim was to describe the potentially severe drug-drug interactions (DDI). &lt;b&gt;&lt;i&gt;Materials and Methods:&lt;/i&gt;&lt;/b&gt; We analyzed Registry of Polytherapies Societa Italiana di Medicina I…

0301 basic medicineDrugMalemedicine.medical_specialtyDeprescriptions020205 medical informaticsDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectElderly; End of life; Limited life expectancy; Polypharmacy; Symptomatic medications; Aged 80 and over; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Male; Polypharmacy; Deprescriptions; Life Expectancy; Patient DischargeSocio-culturale02 engineering and technology03 medical and health sciencesElderly · End of life · Limited life expectancy · Polypharmacy · Symptomatic medicationsPharmacotherapyDeprescriptionsLife ExpectancyElderlySymptomatic medications0202 electrical engineering electronic engineering information engineeringmedicine80 and overHumansLS4_4Medical prescriptionElderly; End of life; Limited life expectancy; Polypharmacy; Symptomatic medicationsmedia_commonAgedPolypharmacyAged 80 and overOriginal Paperbusiness.industryGeneral MedicineElderly End-of-life Limited life expectancy Polypharmacy Preventing medications Symptomatic medicationsElderly End of life Limited life expectancy Polypharmacy Symptomatic medicationsPatient DischargeClonidineLimited life expectancyItalyEmergency medicineEnd of lifeLife expectancyPolypharmacyFemale030101 anatomy & morphologyDeprescribingbusinessmedicine.drugSymptomatic medication
researchProduct